Bajaj Healthcare to acquire Genrx Pharmaceuticals Private Limited
Bajaj Healthcare (BAJAJHCARE) said it has agreed a deal to acquire Genrx Pharmaceuticals Private Limited. The company is valued at about ₹1,113 crore.
What happened
In a filing with the BSE on 14 October 2026 at 04:22 PM, Bajaj Healthcare (BAJAJHCARE) said that it has agreed a deal to acquire Genrx Pharmaceuticals Private Limited.
Company snapshot
Bajaj Healthcare is a small-cap company, with a market value of about ₹1,113 crore.
The stock last traded at ₹330.7, against a 52-week range of ₹272.4–₹490 (32.5% below the high).
Before this filing the shares had moved −0.8% over the month and −4.9% over three months. Average daily turnover over the last 20 sessions was about ₹4.28 crore.
Promoters held 58.59% at the end of Q1 FY27, up 0.30% points from the previous quarter. Foreign institutions owned 2.19% and domestic institutions 1.92%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 149 | 11.8 | 3.74 |
| Q2 FY26 | 148 | 11.1 | 3.53 |
| Q3 FY26 | 161 | 15.7 | 4.96 |
| Q4 FY26 | 153 | -22.9 | -7.16 |
| Q1 FY27 | 166 | 13.7 | 4.07 |
What history shows
BCEIE has no earlier m&a filing from this company on record since May 2026.
Market-wide, 2,054 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
- 17 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.